- Previous Close
1,112.90 - Open
1,111.00 - Bid --
- Ask --
- Day's Range
1,041.50 - 1,128.75 - 52 Week Range
611.20 - 1,335.10 - Volume
199,068 - Avg. Volume
319,097 - Market Cap (intraday)
128.073B - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
28.72 - EPS (TTM)
36.39 - Earnings Date Jul 25, 2024
- Forward Dividend & Yield 43.50 (3.71%)
- Ex-Dividend Date Oct 17, 2023
- 1y Target Est
905.75
Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Nirma Limited.
www.glenmarklifesciences.com2,014
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: GLS.NS
View MorePerformance Overview: GLS.NS
Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLS.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLS.NS
View MoreValuation Measures
Market Cap
136.17B
Enterprise Value
133.33B
Trailing P/E
30.57
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.22
Price/Book (mrq)
5.85
Enterprise Value/Revenue
6.10
Enterprise Value/EBITDA
19.43
Financial Highlights
Profitability and Income Statement
Profit Margin
19.49%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
22.93B
Net Income Avi to Common (ttm)
4.47B
Diluted EPS (ttm)
36.39
Balance Sheet and Cash Flow
Total Cash (mrq)
3.02B
Total Debt/Equity (mrq)
0.74%
Levered Free Cash Flow (ttm)
--